InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the stock.

Other equities research analysts have also issued reports about the stock. Lake Street Capital initiated coverage on shares of InspireMD in a report on Wednesday. They set a “buy” rating and a $5.00 price objective on the stock. Piper Sandler reiterated an “overweight” rating and set a $4.50 price target on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Stock Performance

Shares of NSPR stock opened at $2.95 on Thursday. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.42. The firm has a market capitalization of $76.94 million, a price-to-earnings ratio of -3.93 and a beta of 0.98. The stock’s 50-day simple moving average is $2.66 and its 200-day simple moving average is $2.68.

InspireMD (NYSE:NSPR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The company had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. During the same quarter in the previous year, the firm earned ($0.15) EPS. As a group, equities analysts forecast that InspireMD will post -0.79 earnings per share for the current year.

Institutional Trading of InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC bought a new position in shares of InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned 0.74% of InspireMD as of its most recent SEC filing. 44.78% of the stock is currently owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.